Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 35301507 | 2022 | LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nature cancer Likely relevant The study evaluates Lcor mRNA therapy in combination with anti-PD-L1 in preclinical models, measuring tumor immunogenicity and antigen presentation machinery. | immune-checkpoint blockade; anti-PD-L1; extracellular vesicle Lcor-messenger RNA therapy | Mixed | triple-negative breast cancer | immune-checkpoint blockade 0/0/0; anti-PD-L1 0/15/0; extracellular vesicle Lcor-messenger RNA therapy 0/0/0 | Awaiting curator check |
| 35314795 | 2022 | CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer. British journal of cancer Likely relevant The study tests anti-PD-L1 therapy in murine ovarian cancer models and measures cellular immune composition and T-cell accumulation. | anti-PD-L1 | Animal | ovarian cancer | anti-PD-L1 0/15/0 | Awaiting curator check |
| 35322234 | 2022 | Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature Likely relevant The study demonstrates that androgen receptor blockade and PD-1 targeted therapy in tumour-bearing hosts enhance CD8 T cell function and IFNγ expression while preventing T cell exhaustion. | PD-1 targeted therapy; androgen deprivation therapy | Animal | prostate cancer | PD-1 targeted therapy 0/0/0; androgen deprivation therapy 0/0/0 | Awaiting curator check |
| 35364611 | 2022 | Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer. Molecular cancer therapeutics Likely relevant The study tests a novel bispecific antibody (LY6G6D-TDB) alone and combined with PD-1 blockade in vitro and in mouse xenograft models, measuring T-cell activation and cytotoxicity. | LY6G6D-TDB; anti-PD-1 | Mixed | colorectal cancer | LY6G6D-TDB 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 35392977 | 2022 | Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. Journal of experimental & clinical cancer research : CR Likely relevant The study experimentally tests a bio-nanoparticle vaccine combined with PD-1 blockade in murine models and measures extensive immune cell expansions and shifts. | λ phage vaccine; PD-1 inhibitor | Animal | triple negative breast cancer and hepatocellular carcinoma | λ phage vaccine 0/0/0; PD-1 inhibitor 0/0/0 | Awaiting curator check |
| 35524267 | 2022 | Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer. Journal of nanobiotechnology Likely relevant Tests a nanoparticle-delivered combination of anti-PD-L1 and V9302 in mice and measures CD8+ T cell infiltration, activation, and cytokine levels. | anti-PD-L1 antibody; V9302 | Animal | triple-negative breast cancer | anti-PD-L1 antibody 0/1/0; V9302 0/0/0 | Awaiting curator check |
| 35567985 | 2022 | Rejuvenating hepatic tumor microenvironment immunity with a phosphatidylserine-targeting small molecule drug conjugate. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Likely relevant Tests a small molecule drug conjugate in a mouse model and measures immune cell infiltration, granzyme B, and inflammation-related gene expressions. | conjugate 16b; sorafenib | Animal | hepatocellular carcinoma | conjugate 16b 0/0/0; sorafenib 27/25/7 | Awaiting curator check |
| 35577503 | 2022 | Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. Journal for immunotherapy of cancer Likely relevant The study evaluates combination treatment with emactuzumab and atezolizumab in advanced solid tumor patients and measures changes in CD8+ TILs and TAMs. | emactuzumab; atezolizumab | Patient | advanced solid tumors | emactuzumab 0/0/0; atezolizumab 0/0/4 | Awaiting curator check |
| 35580929 | 2022 | CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. Journal for immunotherapy of cancer Likely relevant The study tests a vaccination strategy combined with PD-1/PD-L1 immunotherapy in mouse models and measures its effects on T cell responses. | anti-PD-1; anti-PD-L1 | Animal | melanoma and colorectal adenocarcinoma | anti-PD-1 14/36/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 35584676 | 2022 | WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell reports Likely relevant The study experimentally tests WEE1 inhibition and PD-L1 blockade in SCLC animal models and measures immune readouts including T cell infiltration and cytokine expression. | AZD1775; PD-L1 blockade | Animal | small cell lung cancer | AZD1775 5/5/0; PD-L1 blockade 0/4/0 | Awaiting curator check |
| 35610387 | 2022 | Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer. Cancer immunology, immunotherapy : CII Likely relevant The study tests a combination of therapies including cisplatin, STING agonist, and ICIs in tumor-bearing mice, measuring T cell populations and cytokine levels. | cisplatin; tumor-specific peptide; neoantigen; DMXAA; immune checkpoint inhibitor | Animal | unspecified cancer | cisplatin 18/3/11; tumor-specific peptide 0/0/0; neoantigen 0/0/0; DMXAA 0/0/0 | Awaiting curator check |
| 35781395 | 2022 | Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors. Journal for immunotherapy of cancer Likely relevant The study tests intravesical bacterial immunotherapy and anti-PD-L1 in an orthotopic mouse model and measures T-cell responses and dendritic cell activation. | MTBVAC; BCG; anti-PD-L1 | Animal | bladder cancer | MTBVAC 0/0/0; BCG 0/0/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 35793868 | 2022 | Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody. Journal for immunotherapy of cancer Likely relevant The study tests an SCD1 inhibitor and anti-PD-1 antibody in mouse tumor models and measures their effects on antitumor T cell responses and dendritic cell recruitment. | SCD1 inhibitor; anti-PD-1 antibody | Animal | colon cancer and non-small cell lung cancer | SCD1 inhibitor 0/0/0; anti-PD-1 antibody 0/2/0 | Awaiting curator check |
| 35802648 | 2022 | PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma. Cancer research Likely relevant The study tests PIM2 kinase inhibition and IL1β blockade combined with ICB in vivo and measures effects on T-cell cytotoxicity and tumor inflammation. | immune checkpoint blockade; IL1β blockade; PIM2 kinase inhibitor | Animal | hepatocellular carcinoma | immune checkpoint blockade 0/1/0; IL1β blockade 0/0/0; PIM2 kinase inhibitor 0/0/0 | Awaiting curator check |
| 35920742 | 2022 | Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing. Clinical cancer research : an official journal of the American Association for Cancer Research Likely relevant The article experimentally tests an LSD1 inhibitor (bomedemstat) and anti-PD-1 therapy in mouse and human models, measuring effects on CD8+ T-cell infiltration, MHC-I expression, and tumor cell killing. | bomedemstat; anti-PD-1 | Mixed | small cell lung cancer | bomedemstat 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 35925680 | 2022 | Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function. The Journal of clinical investigation Likely relevant Investigates miR-155 overexpression in breast cancer cells combined with immune checkpoint blockade in mice, measuring T cell influx and cytokine production. | immune checkpoint blockade | Animal | breast cancer | immune checkpoint blockade 0/1/0 | Awaiting curator check |
| 35926754 | 2022 | Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade. Journal of controlled release : official journal of the Controlled Release Society Likely relevant The study tests Camptothesome in colorectal cancer models and measures immunogenic cell death hallmarks and overall immune responses. | Camptothesome; camptothecin; Onivyde; immune checkpoint inhibitors | Animal | colorectal cancer | Camptothesome 0/0/0; camptothecin 5/0/0; Onivyde 0/0/0; immune checkpoint inhibitors 0/0/0 | Awaiting curator check |
| 35929803 | 2022 | Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. Cancer discovery Likely relevant The study evaluates the immunomodulatory effects of the anticancer drug pembrolizumab in bladder cancer patients and reports immune readouts such as TFH cells and CXCL13. | pembrolizumab | Patient | bladder cancer | pembrolizumab 0/0/16 | Awaiting curator check |
| 36037718 | 2022 | Hydrazide-manganese coordinated multifunctional nanoplatform for potentiating immunotherapy in hepatocellular carcinoma. Journal of colloid and interface science Likely relevant The study experimentally tests a multifunctional nanoplatform delivering doxorubicin and indocyanine green combined with PD-1 blockade in mice with hepatocellular carcinoma and measures various immune parameters. | doxorubicin; indocyanine green; PD-1 blockade | Animal | hepatocellular carcinoma | doxorubicin 22/9/0; indocyanine green 1/2/0; PD-1 blockade 0/0/0 | Awaiting curator check |
| 36050478 | 2022 | Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. Cellular & molecular immunology Likely relevant The study evaluates anti-PD-1 monoclonal antibody treatment in immunocompetent melanoma mouse models and tumor T-cell cocultures, measuring its effects on antitumor immunity. | anti-PD-1 monoclonal antibody | Animal | melanoma | anti-PD-1 monoclonal antibody 0/0/0 | Awaiting curator check |
| 36067356 | 2022 | Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy. Journal of medicinal chemistry Likely relevant The study experimentally tests cyclic anti-PD-L1 peptides in vivo and evaluates PD-1/PD-L1 blocking activity. | cyclic anti-PD-L1 peptides | Animal | cancer | cyclic anti-PD-L1 peptides 0/0/0 | Awaiting curator check |
| 36083892 | 2022 | The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Science immunology Likely relevant The study experimentally tests the microbial metabolite TMAO alone and combined with checkpoint inhibitors in tumor-bearing mice, measuring macrophage polarization and T cell activation. | trimethylamine N-oxide; anti-PD1; anti-Tim3 | Animal | pancreatic ductal adenocarcinoma | trimethylamine N-oxide 0/0/0; anti-PD1 1/1/0; anti-Tim3 0/0/0 | Awaiting curator check |
| 36096533 | 2022 | Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity. Journal for immunotherapy of cancer Likely relevant The study tests an anti-GARP antibody alone and with anti-PD-1 in murine models, evaluating its effects on TGFbeta signaling, T cell exhaustion, and CD8+ T cell trafficking. | PIIO-1; anti-PD-1 | Animal | cancer (general) | PIIO-1 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 36113478 | 2022 | Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity. Cancer cell Likely relevant The study experimentally tests imipramine and VEGF pathway inhibitors, along with anti-PD-L1, in GBM mouse models and measures their effects on T cell infiltration/activation and macrophage reprogramming. | imipramine; anti-programmed death-ligand 1 (PD-L1) | Animal | glioblastoma | imipramine 0/0/0; anti-programmed death-ligand 1 (PD-L1) 0/0/0 | Awaiting curator check |
| 36113897 | 2022 | HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling. Journal for immunotherapy of cancer Likely relevant The study experimentally tests recombinant HSP90alpha on human monocytes and measures its effects on PD-L1, HLA-DR, and T cell suppression. | recombinant HSP90alpha | Mixed | melanoma | recombinant HSP90alpha 0/0/0 | Awaiting curator check |